Automated urine analysis of atypical urothelial cells for urothelial carcinoma: a prospective study

OBJECTIVES: To prospectively evaluate the diagnostic value of atypical urothelial cells (Atyp.C), an automatically determined quantitative parameter of the Sysmex UF-5000 urine particle analyser (Sysmex Corp., Kobe, Japan), as a non-invasive biomarker for urothelial carcinoma (UC). Early diagnosis of UC remains challenging despite advances in diagnostic techniques. While non-invasive urine cytology has high diagnostic value, clinical evidence for Atyp.C in urine remains unclear. Quantification of Atyp.C in urine may improve non-invasive UC disease diagnostics. PATIENTS AND METHODS: Urine samples from 234 patients who underwent invasive urological intervention for non-malignant conditions (control group [CG]) or UC (intervention group [IG]) were considered. Based on histopathology, the IG was subclassified into low-grade (LG) and high-grade (HG) UC and was further grouped into non-muscle-invasive (non-MI) and MI UC. Patients who received neoadjuvant chemotherapy were analysed separately. Atyp.C of ≥0.1 Atyp.C/μL were defined as positive and were automatically quantified using the Sysmex UF-5000 urine particle analyser, which classifies epithelial cells with disproportionately high nucleic acid content relative to cell size. Smoking state, urinary tract infection (UTI), and micro-/macrohaematuria, were evaluated as potential confounding factors. Receiver operating characteristic (ROC) analysis was performed to assess explorative diagnostic Atyp.C performance. RESULTS: The Atyp.C concentration was higher in the IG than in the CG (mean [SEM] 0.53 [0.1] vs 0.29 [0.1] Atyp.C/μL; P = 0.004), with a sensitivity of 0.59. HGUC exhibited higher Atyp.C levels (mean [SEM] 0.85 [0.2] Atyp.C/μL, P < 0.001) and a sensitivity of 0.73. MI UC showed the highest Atyp.C concentrations (mean [SEM] 0.95 [0.4] Atyp.C/μL; P = 0.004) and sensitivity of 0.78. ROC analysis demonstrated the highest diagnostic accuracy for MI UC (area under the ROC curve = 0.75). ROC analysis was exploratory and lacked external validation. UTI was a significant confounder for Atyp.C quantification. CONCLUSION: The Atyp.C are elevated in HGUC, particularly in MI disease, supporting their potential as a non-invasive diagnostic biomarker in UC condition.

Authors

Institutions

Publication Details

Journal
British Journal of Urology
Published
2026-11-02
DOI
https://doi.org/10.1111/bju.70523
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Automated urine analysis of atypical urothelial cells for urothelial carcinoma: a prospective study

Kai Kappert, Katharina Friedrich, Maximillian Reimann, Nathalie Winkler et al.
British Journal of Urology
Bladder and Urothelial Cancer Treatments
article

Automated urine analysis of atypical urothelial cells for urothelial carcinoma: a prospective study

Kai Kappert, Katharina Friedrich, Maximillian Reimann, Nathalie Winkler, Amir Jahić, Jonathan Jeutner, Thorsten Schlomm, Ardita Aleti, Jodie Maksoud
article en

Abstract

OBJECTIVES: To prospectively evaluate the diagnostic value of atypical urothelial cells (Atyp.C), an automatically determined quantitative parameter of the Sysmex UF-5000 urine particle analyser (Sysmex Corp., Kobe, Japan), as a non-invasive biomarker for urothelial carcinoma (UC). Early diagnosis of UC remains challenging despite advances in diagnostic techniques. While non-invasive urine cytology has high diagnostic value, clinical evidence for Atyp.C in urine remains unclear. Quantification of Atyp.C in urine may improve non-invasive UC disease diagnostics. PATIENTS AND METHODS: Urine samples from 234 patients who underwent invasive urological intervention for non-malignant conditions (control group [CG]) or UC (intervention group [IG]) were considered. Based on histopathology, the IG was subclassified into low-grade (LG) and high-grade (HG) UC and was further grouped into non-muscle-invasive (non-MI) and MI UC. Patients who received neoadjuvant chemotherapy were analysed separately. Atyp.C of ≥0.1 Atyp.C/μL were defined as positive and were automatically quantified using the Sysmex UF-5000 urine particle analyser, which classifies epithelial cells with disproportionately high nucleic acid content relative to cell size. Smoking state, urinary tract infection (UTI), and micro-/macrohaematuria, were evaluated as potential confounding factors. Receiver operating characteristic (ROC) analysis was performed to assess explorative diagnostic Atyp.C performance. RESULTS: The Atyp.C concentration was higher in the IG than in the CG (mean [SEM] 0.53 [0.1] vs 0.29 [0.1] Atyp.C/μL; P = 0.004), with a sensitivity of 0.59. HGUC exhibited higher Atyp.C levels (mean [SEM] 0.85 [0.2] Atyp.C/μL, P < 0.001) and a sensitivity of 0.73. MI UC showed the highest Atyp.C concentrations (mean [SEM] 0.95 [0.4] Atyp.C/μL; P = 0.004) and sensitivity of 0.78. ROC analysis demonstrated the highest diagnostic accuracy for MI UC (area under the ROC curve = 0.75). ROC analysis was exploratory and lacked external validation. UTI was a significant confounder for Atyp.C quantification. CONCLUSION: The Atyp.C are elevated in HGUC, particularly in MI disease, supporting their potential as a non-invasive diagnostic biomarker in UC condition.

British Journal of Urology
Humboldt-Universität zu Berlin (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 11%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon